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Hypertension is an exceedingly common disorder in western
societies, and as such practitioners of most clinical special-
ties are likely to encounter patients with acute, severe eleva-
tions in blood pressure. In particular, hypertensive
emergencies and hypertensive urgencies (see the section on
Teminology, definitions, and misconceptions, below) are com-
monly encountered in the emergency department, operating
room, postanaesthesia care unit, and intensive care units
[1–8]. The most important factor that limits morbidity and
mortality from these disorders is prompt and carefully consid-
ered therapy [9]. Unfortunately, hypertensive emergencies
and urgencies are among the most misunderstood and mis-
managed of acute medical problems seen today. Indeed, the
reflex of rapidly lowering an elevated blood pressure is asso-
ciated with significant morbidity and death. Clinicians dealing
with hypertensive emergencies and urgencies should be
familiar with the pathophysiology of the disease and the prin-
ciples of treatment. This article reviews current concepts, and
common misconceptions and pitfalls in the diagnosis and
management of patients with severe hypertension.
Terminology, definitions, and misconceptions
Efforts to classify hypertension on the basis of specific values
have existed for the past 100 years. In the USA, the Joint
National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure has classified hyperten-
sion according to the degree of elevation in blood pressure
[1,10]. According to the most recent report by this committee
(the JNC 7 Report [10]), patients with stage 1 hypertension
have a systolic blood pressure of 140–159mmHg or a dias-
tolic blood pressure of 90–99mmHg. Those patients with
stage 2 hypertension have a systolic blood pressure greater
than 160mmHg or a diastolic blood pressure greater than
100mmHg. Although not specifically addressed in the JNC7
Report, patients with a systolic blood pressure greater than
179mmHg or a diastolic blood pressure that is greater than
109mmHg are usually defined as having ‘severe or acceler-
ated’ hypertension.
A number of different terms have been applied to acute severe
elevations in blood pressure, and the current terminology is
somewhat confusing. However, most authorities have defined
hypertensive crises or emergencies as a sudden increase in
systolic and diastolic blood pressures associated with ‘acute
end-organ damage’ (i.e. cardiovascular, renal, central nervous
system) that requires immediate management. On the other
hand, the term ‘hypertensive urgency’ has been used for
patients with severely elevated blood pressure without acute
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end-organ damage [2–5,8,11,12]. It is important to emphasize
that the clinical distinction between hypertensive emergencies
(crises) and hypertensive urgencies depends on the presence
of acute target organ damage, rather than the absolute level of
blood pressure. Table 1 lists those clinical conditions that meet
the diagnostic criteria for hypertensive emergencies. The term
‘malignant hypertension’ has been used to describe a syn-
drome characterized by elevated blood pressure accompanied
by encephalopathy or acute nephropathy [1,13]. However, this
term has been removed from national and international blood
pressure control guidelines [1,10], and this condition is best
referred to as a hypertensive emergency or crisis.
The dynamic physiologic changes that occur in the early
postoperative period deserve special mention. Postoperative
hypertension has arbitrarily been defined as a systolic blood
pressure greater than 190mmHg and/or diastolic blood pres-
sure greater than 100mmHg on two consecutive readings
following surgery [14,15]. Postoperative hypertension may
have significant adverse sequelae in both cardiac and non-
cardiac patients [16]. The transient but potentially life-threat-
ening nature of postoperative hypertension and the unique
clinical factors present in the postoperative period require
that this clinical syndrome be given individual consideration.
Another group of patients that requires special mention is
those pregnant patients who develop elevations in blood
pressure during, immediately before, or after delivery. The
presence of a systolic pressure greater than 169mmHg or a
diastolic pressure greater than 109mmHg in a pregnant
woman is considered a hypertensive emergency that requires
immediate pharmacologic management [3,17,18].
Epidemiology
Hypertension is an extremely common clinical problem in
western countries. Hypertension affects approximately
50 million people in the USA and approximately 1 billion indi-
viduals worldwide [1,19,20]. Most of these patients have
essential hypertension and approximately 30% are undiag-
nosed [1,19,21]. Furthermore, only between 14% and 29%
of American patients with hypertension have adequate blood
pressure control [19]. The incidence of hypertension
increases with age. In the Framingham heart study [20] the
incidence of hypertension increased in men from 3.3% at age
30–39 years to 6.2% at age 70–79 years. Overall, the preva-
lence and incidence of hypertension are slightly higher in men
than in women [19,20,22,23]. The incidence of hypertension
in African-Americans is about twofold higher than in whites
[19,20,22,23]. The prevalence and incidence of hypertension
in Mexican-Americans are similar to or lower than those in
non-Hispanic whites [19,23,24].
The syndrome of hypertensive emergency was first described
by Volhard and Fahr in 1914 and was characterized by
severe accelerated hypertension, accompanied by evidence
of renal disease and by signs of vascular injury to the heart,
brain, retina and kidney, and by a rapidly fatal course ending
in heart attack, renal failure, or stroke [25]. The first large
study of the natural history of malignant hypertension was
published in 1939 before the widespread use of antihyper-
tensive agents [26]. In that seminal report by Keith and col-
leagues, untreated malignant hypertension had a 1-year
mortality of 79% and a median survival of 10.5 months.
It has been estimated that approximately 1% of patients with
hypertension will develop a hypertensive crises at some point
during their lives [27,28]. Before the advent of antihyperten-
sive therapy, this complication occurred in up to 7% of the
hypertensive population [29]. The epidemiology of hyperten-
sive crises parallels the distribution of essential hypertension
in the community, being much higher among African-Ameri-
cans and the elderly; however, men are affected two times
more frequently than are women [9,12,30,31]. Most patients
who present with a hypertensive crisis have previously been
diagnosed as hypertensive and many have been prescribed
antihypertensive therapy with inadequate blood pressure
control [9,12,30]. The lack of a primary care physician and
failure to adhere to prescribed antihypertensive regimens are
major risk factors for hypertensive emergencies [32]. Tumlin
and colleagues [33] reported that only 51 out of 94 (54%)
patients presenting to an emergency room with a hyperten-
sive emergency had taken their hypertensive medication in
the preceding week. Illicit drug use has also been reported to
be a major risk factor for the development of hypertensive
emergency [32].
Despite the development of increasingly effective antihyper-
tensive treatments over the past 4 decades, the incidence of
hypertensive crisis has increased. Hospital admissions for
hypertensive emergency more than tripled between 1983 and
1990, from 23000/year to 73000/year in the USA [34]. The
reported incidence of postoperative hypertensive crisis varies
depending on the population examined, with most studies
reporting an incidence of between 4% and 35% [15,35,36].
Like other forms of accelerated hypertension, patients with
postoperative hypertensive crisis usually have a prior history
of poorly controlled hypertension [21]. Pregnancy-related
Table 1
Hypertensive emergencies/crises
Hypertensive encephalopathy
Dissecting aortic aneurysm
Acute left ventricular failure with pulmonary edema
Acute myocardial ischemia
Eclampsia
Acute renal failure
Symptomatic microangiopathic hemolytic anemia376
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hypertension (pre-eclampsia) is a form of hypertension that
deserves special mention. Pre-eclampsia occurs in about 7%
of all pregnancies but the incidence varies according to the
patient population, with 70% being nulliparous and 30%
parous [37].
Etiology and pathophysiology
Malignant hypertension can develop de novo or can compli-
cate underlying essential or secondary hypertension
(Table 2). In white patients, essential hypertension accounts
for 20–30% of malignant hypertension. In blacks, however,
essential hypertension is the predominant cause of malig-
nant hypertension, accounting for approximately 80% of all
cases [38,39]. Renal parenchymal disease accounts for up
to 80% of all secondary causes, with chronic pyelonephritis
and glomerulonephritis being the most common diagnoses
[38]. The average age of presentation of essential malignant
hypertension tends to be higher than that for secondary
causes. Secondary causes are almost always found in white
patients presenting under the age of 30 years, whereas
black patients can present with essential hypertension at a
younger age.
The factors that lead to the severe and rapid elevation of
blood pressure in patients with malignant hypertension are
poorly understood. The rapidity of onset suggests a trigger-
ing factor superimposed on pre-existing hypertension. The
risks for developing malignant hypertension are related to
the severity of the underlying hypertension, and therefore
the role of mechanical stress on the vessel wall appears to
be critical in its pathogenesis. The release of humoral vaso-
constrictor substances from the stressed vessel wall is
thought to be responsible for the initiation and perpetuation
of the hypertensive crisis [40,41]. Increased blood pressure
results in endothelial damage, with local intravascular acti-
vation of the clotting cascade, fibrinoid necrosis of small
blood vessels, and release of vasoconstrictor substances
[40,41]. This leads to a vicious cycle of further vascular
injury, tissue ischemia, and release of vasoconstrictor sub-
stances [40,41]. The volume depletion that results from
pressure natriuresis further simulates the release of vaso-
constrictor substances from the kidney. The release of vaso-
constrictor substances from the kidney has long been
postulated to play a central role in the pathophysiology of
malignant hypertension [42]. Activation of the
renin–angiotensin system has been strongly implicated in
the initiation and perpetuation of the vascular injury associ-
ated with malignant hypertension [29,43–45]. In addition to
activation of the renin–angiotensin system, vasopressin,
endothelin, and catecholamines are postulated to play
important roles in the pathophysiology of hypertensive
emergencies [46–49].
Clinical manifestations of hypertensive crises
The clinical manifestations of hypertensive crises are those
associated with end-organ dysfunction (Table 1). Organ dys-
function is uncommon with diastolic blood pressures less
than 130mmHg (except in children and in pregnancy) [21].
However, the absolute level of blood pressure may not be as
important as the rate of increase [7,50,51]. In patients with
longstanding hypertension a systolic blood pressure of
200mmHg or elevations in diastolic pressure up to
150mmHg may be well tolerated without the development of
hypertensive encephalopathy, whereas children or pregnant
women may develop encephalopathy with a diastolic blood
pressure of only 100mmHg [17].
The symptoms and signs of hypertensive crises vary from
patient to patient. Headache, altered level of consciousness,
and/or focal neurologic signs are seen in patients with hyper-
tensive encephalopathy [6,7]. On physical examination, these
patients may have retinopathy with arteriolar changes, hemor-
rhages and exudates, as well as papilledema. In other
patients, the cardiovascular manifestations of hypertensive
crises may predominate, with angina, acute myocardial infarc-
tion, or acute left ventricular failure [9,52]. In some patients,
severe injury to the kidneys may lead to acute renal failure
with oliguria and/or hematuria.
In pregnant patients, the acute elevations in blood pressure
may range from a mild to a life-threatening disease process.
The clinical features vary but may include visual field defects,
severe headaches, seizures, altered mental status, acute
cerebrovascular accidents, severe right upper quadrant
Table 2
Secondary causes of malignant hypertension
Cause Example
Renal parenchymal Chronic pyelonephritis
Primary glomerulonephritis
Tubulointerstitial nephritis
Systemic disorders with  Systemic lupus erythematosus
renal involvement Systemic sclerosis
Vasculitides
Renovascular Atherosclerotic disease
Fibromuscular dysplasia
Polyarteritis nodosa
Endocrine Pheochromocytoma
Conn’s syndrome (primary 
hyperaldosteronism)
Cushing’s syndrome
Drugs Cocaine
Amphetamines
Ciclosporin
Clonidine withdrawal
Phencyclidine
Coarctation of the aorta
Pre-eclampsia/eclampsia377
abdominal pain, congestive heart failure, and oliguria. In the
vast majority of cases, this process can only be terminated by
delivery. The decision to continue the pregnancy or to deliver
should be made following consultation between medical and
obstetric personnel [18,37,53,54].
One syndrome that warrants special consideration is aortic
dissection. Approximately 2000 new cases occur in the USA
each year [55,56]. Aortic dissection should be considered a
likely diagnostic possibility in patients presenting to the emer-
gency department with acute chest pain and elevated blood
pressure. Left untreated, about three-quarters of patients with
type A dissection die within 2 weeks of an acute episode, but
with successful initial therapy the 5-year survival rate
increases to 75% [55,56]. Hence, timely recognition of this
disease entity coupled with urgent and appropriate manage-
ment is the key to a successful outcome in a majority of
patients. It is important to understand that the propagation of
the dissection is dependent not only on the elevation in blood
pressure itself but also on the velocity of left ventricular ejec-
tion [55–58]. For this reason, the aim of antihypertensive
therapy is to lessen the pulsatile load or aortic stress by low-
ering the blood pressure. Specific targets are the blood pres-
sure and rate of pressure rise.
Evaluation and management of hypertensive
crises
A targeted medical history and physical examination sup-
ported by appropriate laboratory evaluation is required in
patients presenting with a possible hypertensive crisis [7,28].
The patient’s hypertensive history and prior blood pressure
control should be ascertained, as should any history of renal
and cardiac disease. The use of prescribed or nonprescribed
medications, and recreational drugs should be determined.
The blood pressure in both arms should be measured by the
physician. In obese patients appropriately sized cuffs should
be used. Physical examination should include palpation of
pulses in all extremities, auscultation for renal bruits, a focused
neurologic examination, and a funduscopic examination.
A complete blood count and smear (to exclude a microangio-
pathic anemia), electrolytes, blood urea nitrogen, creatinine,
urinalysis, and electrocardiogram should be obtained in all
patients. A chest radiograph should be obtained in patients
with shortness of breath or chest pain, and a head computed
tomography scan should be obtained in patients with neuro-
logic symptoms [7,28]. In patients with unequal pulses and/or
evidence of a widened mediastinum on the chest radiograph,
a chest computed tomography or magnetic resonance
imaging scan should be considered [55,56]. Patients in
whom an aortic dissection is considered should not undergo
transesophageal echocardiography until the blood pressure
has been adequately controlled. One the basis of the clinical
evaluation, the physician should be able to make the distinc-
tion between a hypertensive emergency/crisis and a hyper-
tensive urgency [21].
Initial therapeutic approach
The majority of patients with severe hypertension (diastolic
pressure >109mmHg) will have no acute end-organ damage
(hypertensive urgencies). In these patients the blood pres-
sure should be lowered gradually over a period of
24–48 hours, usually with oral medication. Rapid reduction in
blood pressure in these patients may be associated with sig-
nificant morbidity [59–61]. In patients with true hypertensive
emergencies, rapid but controlled lowering of blood pressure
is indicated to limit and prevent further organ damage
[2,27,28,58,61]. However, the blood pressure should not be
lowered to normal levels [3–5,11,12]. Most patients with
hypertensive emergencies are chronically hypertensive and
will have a rightward shift of the pressure–flow (cerebral,
renal, and coronary) autoregulation curve (Fig.1) [62]. Rapid
reduction in blood pressure below the cerebral, renal, and/or
coronary autoregulatory range will result in a marked reduc-
tion in organ blood flow, leading to ischemia and infarction
[21]. For this reason all patients with a hypertensive emer-
gency should be managed in an intensive care unit, where the
patient can be closely monitored. Intra-arterial blood pressure
monitoring may be required in patients with blood pressure
that is labile and difficult to control.
A variety of different antihypertensive agents are available for
use in patients with hypertensive crises. The agent(s) of
choice will depend on the end-organ involved as well as the
monitoring environment (Table 3). Rapid acting intravenous
agents should not be used outside the intensive care unit
because a precipitous and uncontrolled fall in blood pressure
may have lethal consequences. Reductions in diastolic blood
pressure by 10–15% or to about 110mmHg is generally rec-
ommended. This is best achieved by an continuous infusion
of a short acting, titratable, parenteral antihypertensive agent
[21]. In patients with a dissecting aneurysm this goal should
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Figure 1
Cerebral autoregulation in normotensive and chronically hypertensive
patient.
Cerebral blood flow
Mean arterial pressure
60 mmHg  120 mmHg 160 mmHg
Normal
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be achieved within 5–10 min. In all other patients, this end-
point should be achieved within 1 hour. Once the end-points
of therapy have been reached, the patient can be started on
oral maintenance therapy and the intravenous agent weaned
off. It should be noted that most patients with hypertensive
emergencies are volume depleted. Volume repletion with
intravenous crystalloid will serve to restore organ perfusion
and prevent the precipitous fall in blood pressure that may
occur with antihypertensive therapy.
It should be emphasized that only patients with hypertensive
emergencies require immediate reduction in markedly ele-
vated blood pressure. In all other patients the elevated blood
pressure can be lowered slowly using oral agents. Lowering
the blood pressure in patients with ischemic strokes may
reduce cerebral blood flow, which because of impaired
autoregulation may result in further ischemic injury. The
common practice of ‘normalizing’ blood pressure following a
cerebrovascular accident is potentially dangerous. When a
proximal arterial obstruction results in a mild stroke, a fall in
blood pressure may result in further infarction involving the
entire territory of that artery. The current recommendation of
the American Heart Association is that hypertension in the
setting of acute ischemic stroke should only be treated ‘rarely
and cautiously’ [63,64]. It is generally recommended that
antihypertensive therapy be reserved for patients with a dias-
tolic pressure greater than 120–130mmHg, aiming to reduce
the pressure by no more than an arbitrary figure of 10–15%
in the first 24 hours. This approach is supported by a study
reported by Semplicini and colleagues [65]. Those investiga-
tors demonstrated that a higher initial blood pressure was
associated with a better neurologic outcome following an
acute ischemic stroke. They suggested that hypertension may
be protective during an acute ischemic stroke and that lower-
ing the blood pressure may be potentially harmful. In patients
with intracerebral hematomas there is almost always a rise in
intracranial pressure with reflex systemic hypertension. There is
no evidence that hypertension provokes further bleeding in
patients with intracranial hemorrhage. However, a precipitous
fall in systemic blood pressure will compromise cerebral perfu-
sion. The controlled lowering of the blood pressure is currently
recommended only when the systolic blood pressure is greater
than 200mmHg or the diastolic pressure is greater than
110mmHg [66–68]. This recommendation is supported by a
recent study that demonstrated that the rapid decline in blood
pressure within the first 24 hours after presentation was asso-
ciated with increased mortality in patients with an intracranial
hemorrhage [69]. The rate of decline in blood pressure was
independently associated with increased mortality.
Pregnant patients with hypertensive crises represent a
special group of patients. In these patients, intravenous drug
therapy is reserved for those patients with systolic blood
pressure persistently greater than 180mmHg or diastolic
blood pressure persistently greater than 110mmHg
(105mmHg in some institutions) [70]. Before delivery it is
desirable to maintain the diastolic blood pressure greater
than 90mmHg because this pressure allows for adequate
utero-placental perfusion. If the diastolic blood pressure
decreases to below 90mmHg, then decreased uteroplacen-
tal perfusion may precipitate acute fetal distress progressing
to an in utero death or to perinatal asphyxia [18].
Pharmacologic agents used in the treatment
of hypertensive crises
The ideal pharmacologic agent for the management of hyper-
tensive crises would be fast-acting, rapidly reversible, and
titratable without significant side effects. Although no single
ideal agent exists, a growing number of drugs are available
for the management of hypertensive crises. The agent of
choice in any particular situation will depend upon the
patient’s clinical presentation. The preferred agents include
esmolol, labetalol, fenoldopam, and nicardipine. Phentolamine
and trimethaphan camsylate are less commonly used today;
however, they may be useful in particular situations such as
catecholamine-induced hypertensive crises (i.e. pheochromo-
cytoma) [3,7,27,50,51,57]. Sodium nitroprusside may be
used in patients with acute pulmonary edema and/or severe
left ventricular dysfunction and in patients with aortic dissec-
tion. However, because sodium nitroprusside is extremely
rapid acting and a potent antihypertensive agent, intra-arterial
blood pressure monitoring is required; in addition, sodium
nitroprusside requires special handling to prevent its degra-
dation by light. These factors limit the use of this drug in the
emergency department [33]. Oral and sublingual nifedipine
are potentially dangerous in patients with hypertensive crises
and are not recommended. Clonidine and angiotensin-con-
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Table 3
Recommended antihypertensive agents for hypertensive crises
Condition Preferred antihypertensive agent
Acute pulmonary edema Fenoldopam or nitroprusside in
combination with nitroglycerin
(up to 60 µg/min) and a loop
diuretic
Acute myocardial ischemia Labetalol or esmolol in combination
with nitroglycerin (up to 60 µg/min)
Hypertensive encephalopathy Labetalol, nicardipine, or fenoldopam
Acute aortic dissection Labetalol or combination of
nicardipine or fenoldopam and
esmolol or combination of
nitroprusside with either esmolol or
intravenous metoprolol
Eclampsia Labetalol or nicardipine. Hydralazine
may be used in a non-ICU setting
Acute renal failure/ Fenoldopam or nicardipine
microangiopathic anemia
Sympathetic crisis/cocaine Verapamil, diltiazem, or nicardipine in
overdose combination with a benzodiazepine
ICU, intensive care unit.379
verting enzyme inhibitors are long acting and poorly titratable,
but these agents are particularly useful in the management of
hypertensive urgencies [71–75]. Angiotensin-converting
enzyme inhibitors are contraindicated in pregnancy [73,76].
The recommended intravenous antihypertensive agents are
reviewed briefly below.
Esmolol
Esmolol is an ultra-short-acting, cardioselective, β-adrenergic
blocking agent [77–79]. The onset of action of this agent is
within 60s, with a duration of action of 10–20 min [77–79].
The metabolism of esmolol is via rapid hydrolysis of ester link-
ages by red blood cell esterases and is not dependant upon
renal or hepatic function. Because of its pharmacokinetic
properties, some authors consider it an ‘ideal beta-adrenergic
blocker’ for use in critically ill patients [21]. This agent is avail-
able for intravenous use both as a bolus and as an infusion.
Esmolol is particularly useful in severe postoperative hyper-
tension [80–86]. It is a suitable agent in situations in which
the cardiac output, heart rate, and blood pressure are
increased. It has proven safe in patients with acute myocar-
dial infarction, even those who have relative contraindications
to  β-blockers [87]. Typically, the drug is given as a
0.5–1mg/kg loading dose over 1 min, followed by an infusion
starting at 50µg/kg per min and increasing up to 300µg/kg
per min as necessary.
Fenoldopam
Fenoldopam has recently been approved for the management
of severe hypertension in the USA. It is a dopamine agonist
(DA1 agonist) that is short acting and has the advantages of
increasing renal blood flow and sodium excretion [88,89].
Fenoldopam has relatively unique actions and represents a
new category of antihypertensive medication. Although the
structure of fenoldopam is similar to that of dopamine,
fenoldopam is highly specific for only DA1 receptors and is
10 times more potent than dopamine as a renal vasodilator
[90]. Fenoldopam is rapidly and extensively metabolized by
conjugation in the liver, without the participation of
cytochrome P450 enzymes. The onset of action is within
5 min, with the maximal response being achieved by 15 min
[91–93]. The duration of action is between 30 and 60 min,
with the pressure gradually returning to pretreatment values
without rebound once the infusion is stopped [91–93]. No
adverse effects have been reported [91]. The dose rate of
fenoldopam must be individualized according to body weight
and according to the desired rapidity and extent of the phar-
macodynamic effect. An initial starting dose of 0.1µg/kg per
min is recommended. Fenoldopam has been demonstrated to
cause a consistent dose-related decrease in blood pressure
in the dose range 0.03–0.3µg/kg per min [33]. Fenoldopam
has been demonstrated to improve creatinine clearance,
urine flow rates, and sodium excretion in severely hyperten-
sive patients with both normal and impaired renal function
[89,94,95]. It may therefore be the drug of choice in severely
hypertensive patients with impaired renal function [96].
Labetalol
Labetalol is a combined selective α1- and nonselective
β-adrenergic receptor blocker with an α to β blocking ratio of
1:7 [97]. Labetalol is metabolized by the liver to form an inac-
tive glucuronide conjugate [98]. The hypotensive effect of
labetalol begins within 2–5 min after its intravenous adminis-
tration, reaching a peak at 5–15 min after administration and
lasting for about 2–4 hours [98,99]. Because of its β-blocking
effects, the heart rate is either maintained or slightly reduced.
Unlike pure β-adrenergic blocking agents, which decrease
cardiac output, labetalol maintains cardiac output [100].
Labetalol reduces the systemic vascular resistance without
reducing total peripheral blood flow. In addition, the cerebral,
renal, and coronary blood flows are maintained [100–103].
This agent has been used in the setting of pregnancy-induced
hypertensive crisis because little placental transfer occurs,
mainly due to the drug’s negligible lipid solubility [100].
Labetalol may be given as a loading dose of 20mg, followed
by repeated incremental doses of 20–80mg given at 10-min
intervals until the desired blood pressure is achieved. Alterna-
tively, after the initial loading dose, an infusion commencing at
1–2mg/min and uptitrated until the desired hypotensive
effect is achieved is particularly effective. Bolus injections of
1–2mg/kg have been reported to produce precipitous falls in
blood pressure and should therefore be avoided [104].
Nicardipine
Nicardipine is a second generation dihydropyridine derivative
calcium channel blocker with high vascular selectivity and
strong cerebral and coronary vasodilatory activities. It is
100 times more water soluble than is nifedipine, and there-
fore it can be administered intravenously, making nicardipine
an easily titratable intravenous calcium channel blocker
[105,106]. The onset of action of intravenous nicardipine is
between 5 and 15 min with a duration of action of 4–6 hours.
Once administered intravenously, nicardipine crosses the
blood–brain barrier and reaches the nervous tissue, where it
binds to calcium-channels of the L-type, acting primarily at
the level of the hippocampus [107]. Intravenous nicardipine
has been shown to reduce both cardiac and cerebral
ischemia [108]. The appropriate dosage of nicardipine is
independent of the patient’s weight, with an initial infusion
rate of 5mg/hour, increasing by 2.5mg/hour every 5 min to a
maximum of 30mg/hour until the desired blood pressure
reduction is achieved [21].
Nitroprusside
Sodium nitroprusside is an arterial and venous vasodilator
that decreases both afterload and preload [109–113]. Nitro-
prusside decreases cerebral blood flow while increasing
intracranial pressure – effects that are particularly disadvanta-
geous in patients with hypertensive encephalopathy or follow-
ing a cerebrovascular accident [114–117]. Nitroprusside is a
very potent agent, with onset of action within seconds, a
duration of action of 1–2min, and a plasma half-life of
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3–4 min [109–113,118]. In patients with coronary artery
disease a significant reduction in regional blood flow (coro-
nary steal) can occur [119]. In a large randomized, placebo-
controlled trial, nitroprusside was shown to increase mortality
when infused in the early hours after acute myocardial infarc-
tion (mortality at 13 weeks, 24.2% versus 12.7%) [120].
Nitroprusside contains 44% cyanide by weight [112]. Cyanide
is released nonenzymatically from nitroprusside, the amount
generated being dependent on the dose of nitroprusside
administered. Cyanide is metabolized in the liver to thiocyanate
[112]. Thiosulfate is required for this reaction [112,121]. Thio-
cyanate is 100 times less toxic than cyanide. The thiocyanate
generated is excreted largely through the kidneys. Cyanide
removal therefore requires adequate liver function, adequate
renal function, and adequate bioavailability of thiosulfate.
Nitroprusside may cause cytotoxicity because of the release
of cyanide with interference with cellular respiration
[122,123]. Cyanide toxicity has been documented to result in
‘unexplained cardiac arrest’, coma, encephalopathy, convul-
sions, and irreversible focal neurologic abnormalities
[113,124]. The current methods of monitoring for cyanide
toxicity are insensitive. Metabolic acidosis is usually a preter-
minal event. In addition, a rise in serum thiocyanate levels is a
late event and not directly related to cyanide toxicity. Red
blood cell cyanide concentrations (although not widely avail-
able) may be a more reliable method of monitoring for
cyanide toxicity [112]. A red blood cell cyanide concentration
above 40nmol/ml results in detectable metabolic changes.
Levels above 200nmol/ml are associated with severe clinical
symptoms and levels greater than 400nmol/ml are consid-
ered lethal [112]. Data suggest that nitroprusside infusion
rates in excess of 4µg/kg per min for as little as 2–3 hours
may lead to cyanide levels that are within the toxic range
[112]. The recommended doses of nitroprusside of up to
10µg/kg per min result in cyanide formation at a far greater
rate than human beings can detoxify. Sodium nitroprusside
has also been demonstrated to cause cytotoxicity through the
release of nitric oxide, with hydroxyl radical and peroxynitrite
generation leading to lipid peroxidation [122,125–127].
Recently, Khot and colleagues [128] reported the use of nitro-
prusside in 25 normotensive patients with severe aortic steno-
sis and left ventricular dysfunction. After 24 hours of
nitroprusside infusion (mean dose of 128µg/min) there was a
significant increase in the mean cardiac index to
2.52±0.55l/min per m2 from a baseline value of
1.60±0.35l/min per m2; this was associated with a significant
increase in stroke volume and a significant fall in the systematic
vascular resistance and pulmonary capillary wedge pressure.
The nitroprusside was well tolerated, had minimal side effects,
and was associated with an improvement in renal function. It
should be emphasized that, in this study, the patients received
the nitroprusside infusion for no longer than 24 hours and the
maximum dose did not exceed 2µg/kg per min.
Considering the potential for severe toxicity with nitroprus-
side, this drug should only be used when other intravenous
antihypertensive agents are not available and then only in
specific clinical circumstances and in patients with normal
renal and hepatic function [113]. The duration of treatment
should be as short as possible and the infusion rate should
not exceed 2µg/kg per min. An infusion of thiosulfate should
be used in patients receiving higher dosages (4–10µg/kg
per min) of nitroprusside [121]. It has also been demon-
strated that hydroxocobalamin (vitamin 12a) is safe and effec-
tive in preventing and treating cyanide toxicity associated with
the use of nitroprusside. This may be given as a continuous
infusion at a rate of 25mg/hour. Hydroxocobalamin is unsta-
ble and should be stored dry and protected from light.
Cyanocobalamin (vitamin B12), however, is ineffective as an
antidote and is not capable of preventing cyanide toxicity.
Nifedipine, nitroglycerin, and hydralazine
Nifedipine, nitroglycerin, and hydralazine are not recom-
mended in the management of hypertensive emergencies.
The bases of these recommendations are discussed below.
Nifedipine
Nifedipine has been widely used via oral or sublingual admin-
istration in the management of hypertensive emergencies,
severe hypertension associated with chronic renal failure,
perioperative hypertension, and pregnancy induced hyperten-
sion [72,129–136]. Although nifedipine has been given via
the sublingual route, the drug is poorly soluble and is not
absorbed through the buccal mucosa. However, it is rapidly
absorbed from the gastrointestinal tract after the capsule is
broken/dissolved [137]. This mode of administration has not
been approved by the US Food and Drug Administration. A
significant decrease in blood pressure is usually observed
5–10 min after nifedipine administration, with a peak effect at
between 30 and 60 min and a duration of action of approxi-
mately 6–8 hours [129].
Sudden uncontrolled and severe reductions in blood pres-
sure accompanying the administration of nifedipine may pre-
cipitate cerebral, renal, and myocardial ischemic events,
which have been associated with fatal outcomes
[72,108,130–133,137–140]. Elderly hypertensive patients
with underlying organ impairment and structural vascular
disease are more vulnerable to the rapid and uncontrolled
reduction in arterial pressure [138]. Given the seriousness of
the reported adverse events and the lack of any clinical docu-
mentation attesting to a benefit, the use of nifedipine
capsules for hypertensive emergencies and ‘pseudo-
emergencies’ should be abandoned [138]. The Cardiorenal
Advisory Committee of the US Food and Drug Administration
has concluded that the practice of administering sublingual/
oral nifedipine should be abandoned because this agent is
neither safe nor efficacious [141].
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Nitroglycerin, hydralazine, and diuretics
Nitroglycerin is a potent venodilator, and only at high doses
does it affect arterial tone [142]. It causes hypotension and
reflex tachycardia, which are exacerbated by the volume
depletion characteristic of hypertensive emergencies. Nitro-
glycerin reduces blood pressure by reducing preload and
cardiac output, which are undesirable effects in patients with
compromised cerebral and renal perfusion. Low dose
(60mg/min) nitroglycerin may, however, be used as an
adjunct to intravenous antihypertensive therapy in patients
with hypertensive emergencies associated with acute coro-
nary syndromes or acute pulmonary edema.
Hydralazine is a direct acting vasodilator. Following intramuscu-
lar or intravenous administration there is an initial latency period
of 5–15 min followed by a progressive and often precipitous
fall in blood pressure that can last up to 12 hours [143,144].
Although hydralazine’s circulating half-life is only about 3 hours,
the half-time of its effect on blood pressure is about 100 hours
[145–148]. Because of hydralazine’s prolonged and unpre-
dictable antihypertensive effects and the inability to titrate the
drug’s hypotensive effect effectively, hydralazine is best
avoided in the management of hypertensive crises.
Volume depletion is common in patients with malignant
hypertension, and the administration of a diuretic together
with a hypertensive agent can lead to a precipitous drop in
blood pressure. Diuretics should be avoided unless specifi-
cally indicated for volume overload as occurs in renal
parenchymal disease or coexisting pulmonary edema.
Conclusion
Patients with hypertensive crises may require immediate
reduction in elevated blood pressure to prevent and arrest
progressive end-organ damage. The best clinical setting in
which to achieve this blood pressure control is in the inten-
sive care unit, with the use of titratable intravenous hypoten-
sive agents. There are several antihypertensive agents
available for this purpose, including esmolol, nicardipine,
labetalol, and fenoldopam. Although sodium nitroprusside is a
rapid acting and potent antihypertensive agents, it may be
associated with significant toxicity and should therefore only
be used in select circumstances and at a dose that should
not exceed 2µg/kg per min. The appropriate therapeutic
approach in each patient will depend on the clinical presenta-
tion. Agents such as nifedipine and hydralazine should be
abandoned because these agents are associated with signifi-
cant toxicities and/or side effects.
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